| Literature DB >> 36175792 |
Eric P Rahrmann1, David Shorthouse2, Amir Jassim1, Linda P Hu1, Mariaestela Ortiz3, Betania Mahler-Araujo4, Peter Vogel5, Marta Paez-Ribes1, Atefeh Fatemi1, Gregory J Hannon1, Radhika Iyer6, Jay A Blundon7, Filipe C Lourenço1, Jonathan Kay8, Rosalynn M Nazarian9, Benjamin A Hall2, Stanislav S Zakharenko7, Douglas J Winton1, Liqin Zhu10, Richard J Gilbertson11,12.
Abstract
We identify the sodium leak channel non-selective protein (NALCN) as a key regulator of cancer metastasis and nonmalignant cell dissemination. Among 10,022 human cancers, NALCN loss-of-function mutations were enriched in gastric and colorectal cancers. Deletion of Nalcn from gastric, intestinal or pancreatic adenocarcinomas in mice did not alter tumor incidence, but markedly increased the number of circulating tumor cells (CTCs) and metastases. Treatment of these mice with gadolinium-a NALCN channel blocker-similarly increased CTCs and metastases. Deletion of Nalcn from mice that lacked oncogenic mutations and never developed cancer caused shedding of epithelial cells into the blood at levels equivalent to those seen in tumor-bearing animals. These cells trafficked to distant organs to form normal structures including lung epithelium, and kidney glomeruli and tubules. Thus, NALCN regulates cell shedding from solid tissues independent of cancer, divorcing this process from tumorigenesis and unmasking a potential new target for antimetastatic therapies.Entities:
Year: 2022 PMID: 36175792 DOI: 10.1038/s41588-022-01182-0
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 41.307